Compare ICFI & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICFI | TRVI |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2006 | 2019 |
| Metric | ICFI | TRVI |
|---|---|---|
| Price | $97.22 | $10.83 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $99.25 | $20.38 |
| AVG Volume (30 Days) | 129.5K | ★ 1.5M |
| Earning Date | 02-26-2026 | 11-13-2025 |
| Dividend Yield | ★ 0.59% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.30 | N/A |
| Revenue | ★ $1,925,502,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.52 | N/A |
| P/E Ratio | $17.89 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $72.03 | $3.47 |
| 52 Week High | $135.34 | $14.39 |
| Indicator | ICFI | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 72.68 | 35.70 |
| Support Level | $90.95 | $10.99 |
| Resistance Level | $94.99 | $11.78 |
| Average True Range (ATR) | 3.30 | 0.67 |
| MACD | 0.82 | -0.15 |
| Stochastic Oscillator | 95.40 | 9.69 |
ICF International Inc provides professional services and technology-based solutions to government and commercial clients, including management, marketing, technology, and policy consulting and implementation services. Its services support clients that operate in four key markets that include Energy, Environment, Infrastructure and Disaster Recovery; Health and Social Programs and Security and Other Civilian & Commercial. The Company's majority clients are United States federal government departments and agencies. It operates in a single segment, which is providing professional services.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.